Relmada Therapeutics

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder See more here

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results See more here

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder See more here

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 See more here

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results See more here

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology See more here

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results See more here

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential - All doses of REL-1017, including the maximum tolerated dose, demonstrated a statistically significant difference in abuse potential vs. ketamine (p-values <0.05) - All doses of REL-1017, including the maximum tolerated dose, were statistically equivalent to placebo…

Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry - Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD - Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo  - Safety analysis showed adverse event profile comparable to placebo, with…

Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option See more here